

PLASMA β -SECRETASE1 (BACE1) LEVELS AS MARKER OF COGNITIVE FUNCTION DECLINE IN ELDERLY

Syahfira A Syahna¹, M. Ichwan^{1,2*}, Nuraiza Meutia^{1,3}, Jelita Siregar⁴ and Zulham Yamamoto^{1,5}

¹Master Program in Biomedical Sciences, Faculty of Medicine, Universitas Sumatera Utara, syahfirasyahna@gmail.com

²Department of Pharmacology and Therapeutic, Faculty of Medicine, Universitas Sumatera Utara, m.ichwan@usu.ac.id

³Department of Physiology, Faculty of Medicine, Universitas Sumatera Utara, nuraizameutia@gmail.com

⁴Department of Clinical Pathology, Faculty of Medicine, Universitas Sumatera Utara, jelita.siregar@usu.ac.id

⁵Department of Histology, Faculty of Medicine, Universitas Sumatera Utara, zulham@usu.ac.id

Abstract. BACE1 which forms amyloid plaques consisting of amyloid β peptides is a typical neuropathological lesion in the brain of Alzheimer's disease. Many studies have shown that β -amyloid is central to the pathophysiology of Alzheimer's disease and may play an early role in neurodegenerative disorders. The BACE1 enzyme forms amyloid β plaques. The BACE1 protein is detectable in plasma and its levels are significantly increased in patients with mild cognitive impairment and future Alzheimer's. This $A\beta$ peptide accumulates into senile plaques causing the characteristics of Alzheimer's disease, can cause neuronal death and cognitive decline

Keywords: Gene, BACE1, Elderly

Received [12 June 2023] | Revised [20 July] | Accepted [31 August 2023]

1 Introduction

Currently, Indonesia is entering a period of an aging population, which is marked by an increase in life expectancy followed by an increase in the number of elderly people. In 2025 it is estimated that the number of elderly people will increase to 36 million people [28]. The number of elderly

*Corresponding author at: Master Program in Biomedical Sciences, Faculty of Medicine, Universitas Sumatera Utara, Jl. Dr. Mansur No. 5, Medan, Indonesia

E-mail address: m.ichwan@usu.ac.id

people in Indonesia continues to increase from year to year. In 1990 there were 6% in of the elderly. In 2020 it will be 9.3% and it is projected that it will continue to increase to 16% in 2050. Thus it is projected that by 2045, the elderly population in Indonesia will make up almost one-fifth of the total population [3].

One of the problems encountered by the elderly is impaired cognitive function, cognitive impairment in the elderly that begins with mild cognitive impairment varies, consisting of mild amnesic cognitive impairment, non-amnesic mild cognitive impairment, and multi-dominant mild cognitive impairment which will develop into dementia [31]. Amnesic mild cognitive impairment is hypothesized to progress to Alzheimer's disease if there is an underlying degenerative etiology. Amnesic mild cognitive impairment can develop into non-Alzheimer's dementia such as frontotemporal dementia if one domain is affected by a degenerative etiology [27].

Cognitive impairment has an impact on functional abilities and care needs in the elderly. Mild cognitive impairment is diagnosed by the presence of impairment in one or more cognitive domains without meeting the diagnostic criteria for dementia. Nearly 16% of the elderly experience mild cognitive impairment without developing dementia. This is more often found in men than women. Statistical results from mild cognitive impairment to Alzheimer's disease range between 12% and 15%, compared to 1-2% in healthy adults [51].

The cognitive disorder is an important health problem because it will have an impact on the social and economic life of the community. Research in China on changes in cognitive function and risk factors for cognitive impairment in the elderly is still rare. China has become the fastest-growing country in the world for people with a population scale of cognitive impairment. Elderly with mild cognitive impairment may experience cognitive dysfunction, whereas those with severe cognitive impairment may develop dementia or Alzheimer's disease, resulting in loss of capacity to complete daily routines and result in an inability to live independently [55]. Whereas in research in Indonesia from a statistical agency, the number of elderly people will increase every year [3].

2. Factors affecting BACE1

Factors that negatively affect cognitive function include brain damage from cerebral ischemia, head trauma, toxins such as alcohol, stress hormone excess, or the development of degenerative dementias such as Alzheimer's. Factors of a negative impact can cause cumulative damage to the brain with age and result in cognitive impairment. Degenerative dementia is the most common cause of cognitive decline [26]. Figure 1 regarding the differences in the brains of healthy people and brains with Alzheimer's [2].




Figure 1: (a) the brain of a healthy person (b) the brain that has Alzheimer's [2].

3. Structure and Function of the BACE1 Protein

BACE1 is a membrane-bound enzyme from the pepsin family and can cleave the peptide bonds of aspartic and glutamic acids from amyloid precursor proteins [6].

BACE1 is a type 1 membrane protein that, together with BACE2, forms a subfamily of membrane aspartyl proteases [53]. BACE1 was first synthesized in the endoplasmic reticulum as an immature amyloid precursor protein (proBACE1) with a molecular mass of 60 kDa (kiloDalton). The BACE1 gene spans 30 kilobases (kb) on the human chromosome (11q23.2) and spans 9 exons. The BACE-1 gene promoter lacks the typical CAAT and TATA boxes, but the BACE1 gene contains six unique functional domains and three structural domains with sequence complexity preceded by the ATG start codon. Beta-site amyloid precursor protein cleaving enzyme-1 (BACE1) has historically focused on the brain and its action as a β -secretase responsible for the production of amyloid beta peptide ($A\beta$). This $A\beta$ peptide accumulates into senile plaques causing the characteristics of Alzheimer's disease, which can cause neuronal death and cognitive decline [7]. The BACE1 gene is transcribed as a 501 amino acid preprotein, which contains five key domains, a signal peptide, and pro-catalytic, transmembrane, and cytoplasmic domains. The signal peptide delivers the BACE1 preprotein to the endoplasmic reticulum, where furin cleavage of the pro-domain results in the mature BACE1 protein [47]. The transmembrane domain determines the localization of BACE1 to the Golgi end, within the trans-Golgi network BACE1 is activated post-translation. BACE1 protease activity is dependent on the two aspartyl active sites at D93 and D289, as well as the position of the regulatory antiparallel hairpin flap relative to the substrate-binding site.

The activated BACE1 protein then operates on the plasma membrane in endosomes and the functioning Golgi apparatus at an optimal pH of 4.5 [37].

The BACE1 enzyme catalyzes the cleavage of Amyloid Precursor Protein (APP) to produce soluble amyloid precursor protein (sAPP β). The last peptide is then cleaved by β secretase to form the amyloid 42 ($A\beta$ 42) peptide fragment. β secretase and γ secretase form the amyloid

42 peptide fragment ($A\beta$ 42). After that, 42 amyloid β collects and forms senile plaques, senile plaques which are the main neuropathological features of Alzheimer's disease [4]. Amyloid β peptides exist in two forms, namely 40 or 42 amino acids [6].




Figure 2: BACE1 structure. BACE1 crystal structure images were generated using the 3TPR structure using the RSCB Protein Data Bank (<https://www.rcsb.org/>). (a) Structure without annotations (b) Structure of the C3 inhibitor binding (red), the two aspartyl protease active sites (blue) at D93 and D289, and the hairpin-antiparallel flap (green) between Y128–G138 shown (right). The structure of 62 residues is lost [38].

4. BACE1 Substrates and Functions

BACE1 is focused on its role in the amyloidogenic pathway, BACE1 is responsible for the early cleavage of the rate-limiting protein APP. Sequential cleavage by BACE1 and γ -secretase yields the $A\beta$ -40 and $A\beta$ -42 peptides. Despite having approximately 64% homology with BACE1, BACE2 cleaves the APP protein at alternative sites and therefore does not produce the same β -secretase action and $A\beta$ production [44]. BACE2 is also mainly found in peripheral tissues, in contrast to BACE1 which is widely expressed in the brain [1]. BACE1 $A\beta$ -42 production is associated with memory regulation, synaptic function, myelin repair, and Alzheimer's [42]. Alzheimer's is the most common dementia and presents with several physiological changes besides the accumulation of $A\beta$ -42 into extracellular amyloid plaques, including neurofibrillary tangles (NFTs), chronic inflammation, loss of synapses, neuronal death, and hypometabolism [11 and 19]. Accumulation of $A\beta$ plaques interfere with nerve and synaptic function which causes cognitive impairment effects [43]. BACE1 is involved in various metabolic functions [20, 24, and 25]. The physiological role of BACE1 in different cells and organelles, in addition to its role in Alzheimer's. Although the expression of BACE1 is highest in the brain, more is expressed, in other tissues it is lower including endocrine tissue, pancreas, muscle tissue, respiratory tissue, bone marrow, and lymphoid tissue. Because APP is also widely expressed BACE1-mediated $A\beta$ production can have effects on many cells and tissues [42]

5. BACE1 as a marker of impaired cognitive function

Single Nucleotide Polymorphism (SNP) polymorphism of the BACE1 gene can affect the expression of the BACE1 gene and the activity of the BACE1 gene. The BACE1 gene is located on chromosome 11 (11q23.3) and appears to have a genetic variation that can lead to the risk of Alzheimer's disease. SNP can also create phenotypes, there are 23 locations to create polymorphisms, therefore SNP can determine whether a patient is at risk for Alzheimer's disease [50]

A Sampling of BACE1 through blood with plasma sampling. BACE1 as a marker of impaired cognitive function. The BACE1 protein is detectable in plasma and its levels increase significantly in patients with mild cognitive impairment and will become Alzheimer's [35]. The optimal value of BACE1 levels is 20.7 kU/L [5].

6. Conclusion

BACE1 levels in plasma can be used as a marker of cognitive function

7. Suggestion

With this information, BACE1 is used as a screening tool to determine the risk of cognitive impairment so that health workers take preventive measures

8. References

- [1] Bennett BD, Babu-Khan S, Loeloff R, et al. Expression analysis of BACE2 in brain and peripheral tissues. *J Biol Chem*. Vol. 27, No.27. pp 20647-20651. 2000.
- [2] Breijyeh Z & Karaman R Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Vol. 25, No. 24. pp 1-24. 2020.
- [3] Badan Pusat Statistik. 2021. Statistik Penduduk Lanjut Usia.
- [4] Carvellati C, Valacchi G, Zuliani G. BACE-1 role in Alzheimer disease and other dementia: from the theory to the practice. *Neural Regeneration Research*. Vol.16, No.12 pp 2407-8. 2021.
- [5] Carvellati C, Trentini A, Rosta V, Passaro A, Bosi C, Sanz, J et al. Serum beta-secretase 1 (BACE1) activity as candidate biomarker for late-onset Alzheimer's disease. *GeroScience*. Vol.42 No. 1 pp 159–167. 2020.
- [6] Chashmpoosh M, Babaahmadi H, Mousavidehmordi R, Shalbfan B, Mohammadi A, Kheirollah A et al. Association G/C (rs638405) Polymorphism in β -secretase Gene with Alzheimer's Disease. *Avicenna Journal of Medical Biotechnology*. Vol. 10, No.4. pp 242-247. 2018.
- [7] Cole SL, Vassar R. The Alzheimer's disease Beta-secretase enzyme, BACE1. *Mol Neurodegener*. Vol.2, No.1. 2007.
- [8] Farkas E, Luiten PGM. Cerebral microvascular pathology in aging and Alzheimer's disease. *Prog Neurobiol*. Vol. 64, No.6 pp 575-611. 2001.
- [9] Fleck D, van Bebber F, Colombo A, et al. Dual cleavage of neuregulin 1 type III by BACE1 and ADAM17 liberates its EGF-like domain and allows paracrine signaling. *J Neurosci*. Vol.33, No.18 pp 7856-7869. 2013.
- [10] Garry W, Siddarth P, Li Z, Miller K, Ercoli L, Emerson, N et al. Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled. 18-Month Trial. *Journal Geriatr*. Vol. 26, No. 3 pp 266-277. 2016.
- [11] Hammond TC, Xing X, Wang C, et al. β -amyloid and tau drive early Alzheimer's disease decline while glucose hypometabolism drives late decline. *Commun bio*. Vol. 3, No. 1 pp 1-3. 2020.
- [12] Hu X, He W, Diaconu C, et al. Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. *FASEB K*. Vol. 22, No.8 pp 2970-2980. 2008.

- [13] Hu X, He W, Luo X, Tsubota KE, Yan R. BACE1 regulates hippocampal astrogenesis via the Jagged1-notch pathway. *Cell Rep.* Vol. 4, No. 1 pp 40-49. 2013.
- [14] Hu X, Hou H, Bastian C, et al. BACE1 regulates the proliferation and cellular functions of Schwann cells. *Glia.* Vol. 65, No. 5 pp 712-726. 2017.
- [15] Huang Z, Wong L, Su Y, Huang X, Wang N, Chen H et al. 2020. Blood-brain barrier integrity in the pathogenesis of Alzheimer's disease. *Frontiers in Neuroendocrinology.* Vol. 59, No. 100857 pp 1-13. 2020.
- [16] Inyushin M, Zayas-Santiago A, Rojas L, Kucheryavykh Y, Kucheryavykh L. Platelet-generated amyloid beta peptides in Alzheimer's disease and glaucoma. *Histol Histopathol.* Vol.34, No. 8 pp 843-856. 2019.
- [17] Jongsiriyanyong, S and Limpawattana, P. Mild Cognitive Impairment in Clinical Practice: A Review Article. *American Journal of Alzheimer's Disease & Other Dementias.* Vol. 33, No. 8 pp 500-507. 2018.
- [18] Kalara RN. Vascular factors in Alzheimer's disease. *Int Psychogeriatr.* Vol. 15 pp 47-52. 2003.
- [19] Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer's disease. *Alzheimer's Dement: Transl Res Clin Interv.* Vol. 4, No. 1 pp 575-590. 2018.
- [20] Kitazume S, Nakagawa K, Oka R, et al. In vivo cleavage of alpha2,6-sialyltransferase by Alzheimer beta-secretase. *J Biol Chem.* Vol. 280, No. 9 pp 8589-8595. 2005.
- [21] Kuhn PH, Koroniak K, Hogg S, et al. Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. *EMBO J.* Vol. 31. No. 14 pp 3157-3168. 2012.
- [22] Kuhn PH, Marjaux E, Imhof A, De Strooper B, Haass C, Lichtenthaler SF. Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase. *J Biol Chem.* Vol. 282, No.16 pp 11982-11995. 2007.
- [23] Meakin PJ, Harper AJ, Hamilton DL, et al. Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice. *Biochem J.* Vol. 441, No. 1. pp 85-296. 2012.
- [24] Meakin PJ, Jaliczy SM, Montagut G, et al. BACE1-dependent amyloid processing regulates hypothalamic leptin sensitivity in obese mice. *Sci Rep.* Vol. 8, No.1 pp 1-16. 2018.
- [25] Meakin PJ, Mezzapasa A, Benabou E, et al. The beta secretase BACE1 regulates the expression of insulin receptor in the liver. *Nat Commun.* Vol. 9, No.1036 pp 1-14. 2018.
- [26] Murman D. The Impact of Age on Cognition. *Seminars in Hearing.* Vol. 36, No. 3 pp 111-121. 2015.
- [27] Petersen R, Knopman D, Bradley B, Yonas G, Robert I, Smith G, Rosebud R, Jack C. Mild Cognitive Impairment: Ten Years Later. *Arch Neurol.* Vol. 66, No. 12 pp 1447-1455. 2009.
- [28] Peraturan Kementerian Kesehatan Republik Indonesia nomor 67. Penyelenggaraan pelayanan kesehatan lanjut usia di pusat kesehatan masyarakat. 2015.
- [29] Pignoni M, Wanngren J, Kuhn PH, et al. Seizure protein 6 and its homolog seizure 6-like protein are physiological substrates of BACE1 in neurons. *Mol Neurodegener.* Vol. 11, No. 1 pp 67. 2016.
- [30] Prince M, Ali G, Guerchet M, Prina A, Albanese E, Wu Y et al. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. *Alzheimer's Research & Therapy.* Vol. 8, No. 23 pp 1-13. 2016
- [31] Robert R & Knopmann D. Classification and Epidemiology of MCI. NIH Public Access. Vol 29, No. 4 pp 1-18. 2013.
- [32] Radford J. Vascular Cognitive Impairment. *American Academic of Neurology.* Vol. 25, No. 1 pp 147-164. 2019.
- [33] Rossner S, Sastre M, Bourne K, Lichtenthaler SF. Transcriptional and translational regulation of BACE1 expression—implications for Alzheimer's disease. *Prog Neurobiol.* Vol. 79, No. 2 pp 95-111. 2006
- [34] Sahathevan R, Brodtmann, A, Donnan G A. Dementia, stroke, and vascular risk factors: A review. 2012. *International Journal of Stroke,* Vol. 7, No. 1 pp 61–73. 2012.
- [35] Shen Y, Wang H, Sun Q, Yao H, Keegan AP, Mullan M, Wilson J, Lista S, Leyhe T, Laske C, Rujescu D, Levey A, Wallin A, Blennow K, Li R, Hampel H. Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment. *Biol Psychiatry.* Vol. 83, No. 5 pp 447-455. 2018.
- [36] Simpson I, Ponnuru P, Klinger M, Myers R, Devraj K, Coe C. A novel model for brain iron uptake: introducing the concept of regulation. *Journal Cerebral Blood Flow & Metabolism.* Vol . 35, No. 1 pp 48-57. 2015.
- [37] Shimizu H, Tosaki A, Kaneko K, Hisano T, Sakurai T, Nukina N. Crystal structure of an active form of BACE1, an enzyme responsible for amyloid β protein production. *Mol Cell Biol.* Vol. 28, No. 11 pp 3663-3671. 2008.
- [38] Taylor H, Przemyska L, Clavane E, Meakin P. BACE1: More than just β secretase. 2022. 1-17.

- [39] TCW J & Goate, A. Genetics of β -Amyloid Precursor Protein in Alzheimer's Disease. *Cold Spring Harb Perspect Med*. Vol. 7, No. 6 pp 1-11. 2017
- [40] Tifratene K., Sakarovitch C, Rouis A, Pradier C, Robert, P. Mild cognitive impairment and anti-Alzheimer disease medications: A cross sectional study of the French National Alzheimer Databank (BNA). *Journal of Alzheimer's Disease*, Vol. 38, No. 3 pp 541–549. 2014.
- [41] Uddin M, Kabir M, Tewari D, Al Mamun A, Mathew B, Aleya L et al. 2020. Revisiting the role of brain and peripheral A β in the pathogenesis of Alzheimer's disease. *Journal of the Neurological Science*. pp 1-46. 2020.
- [42] Uhlen M, Fagerberg L, Hallström BM, et al. Proteomics. Tissue-based map of the human proteome. *Science*. Vol 347, No. 6220. 2015.
- [43] Vassar R, Kovacs DM, Yan R, Wong PC. The β -secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. *J Neurosci*. Vol . 29, No. 41 pp 12787-12794. 2009.
- [44] Vassar R, Kuhn PH, Haass C, et al. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. *J Neurochem*. Vol. 130, No. 1 pp 4-28. 2014.
- [45] Vassar R. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. *Science*. Vol. 286, No. 5440 pp 735-741. 1999.
- [46] Wang D, Chen F, Han Z, Yin Z, Ge X, Lei P. 2021. Relationship Between Amyloid- β Deposition and Blood–Brain Barrier Dysfunction in Alzheimer's Disease. *Frontier in Cellular Neuroscience*. Vol. 15, No. 695479 pp 1-14. 2021.
- [47] Wang H, Li R, Shen Y. β -Secretase: its biology as a therapeutic target in diseases. *Trends Pharmacol Sci*. Vol. 34, No. 4 pp 215-225. 2013.
- [48] Wang LL, Liu JH, Wang Q, et al. MicroRNA-200a-3p mediates neuroprotection in Alzheimer-related deficits and attenuates amyloid-beta overproduction and tau hyperphosphorylation via coregulating BACE1 and PRKACB. *Front Pharmacol*. Vol. 10. 2019.
- [49] Wium-Andersen IK, Rungby J, Jørgensen MB, Sandbæk A, Osler M, Wium-Andersen MK. Risk of dementia and cognitive dysfunction in individuals with diabetes or elevated blood glucose. *Epidemiol Psychiatr Sci*. 2019.
- [50] Yu M, Liu Y, Shen J, Lv D, Zhang J. 2016. Meta-analysis of BACE1 gene rs638405 polymorphism and the risk of Alzheimer's disease in Caucasian and Asian population. *Neuroscience Letters*. pp 189-296. 2016.
- [51] WHO. Evidence Profile: Cognitive Impairment. *ICOPE Guideline*. pp. 1-20. 2017.
- [52] Yan R, Bienkowski MJ, Shuck ME, et al. Membrane-anchored aspartyl protease with Alzheimer's disease β -secretase activity. *Nature*. Vol 402, No. 6761 pp 533-537. 1999.
- [53] Yan R. Physiological functions of the β -site amyloid precursor protein cleaving enzyme 1 and 2. *Front Molec Neurosci*. 2017.
- [54] Yuan H, Ling K, Du X, Ge P, Wu S, Wang X et al. The association of three BACE1 gene polymorphisms (exon5 C/G, intron 5 T/G and 3'UTR T/A) with sporadic Alzheimer's disease susceptibility: a meta-analysis. *International Journal of Clinical and Experimental Medicine*. Vol. 8, No. 8 pp 12264-74. 2015.
- [55] Zhang Q, Wu Y, Han T, Liu E. Changes in Cognitive Function and Risk Factors for Cognitive Impairment of the Elderly in China: 2005–2014. *International Journal. Environment. Research. Public Health*. Vol. 16, No. 16 pp 1-13. 2019.
- [56] Zhang Z, Huang J, Shen Y, Li R. BACE1-dependent neuregulin-1 signaling: an implication for schizophrenia. *Front Mol Neurosci*. 2017
- [57] Zhao X, Zeng H, Lei L, Tong X, Yang L, Yang Y et al. Tight junctions and their regulation by non-coding RNAs. *International of Journal Biological Science*. Vol. 17, No. 3 pp 712-727. 2021.
- [58] Zu Y, Liu H, Lu X, Zhang B, Weng W, Yang J et al. Prevalence of dementia in the People's Republic of China from 1985 to 2015: a systematic review and meta-regression analysis. *BMC Public Health*. Vol 19, No. 578 pp 1-10. 2019.
- [59] Zuliani G, Trentini A, Rosta, V, Guerrini R, Pacifico S et al. Increased blood BACE1 activity as a potential common pathogenic factor of vascular dementia and late onset Alzheimer's disease *Scientific Report*. 2020.